{"version":"https://jsonfeed.org/version/1","title":"Route Consulting ","home_page_url":"https://routeconsultingllc.com","description":"Route Consulting ","author":{"name":"Route Consulting "},"items":[{"id":"https://routeconsultingllc.com/resources/f/launch-readiness-is-no-longer-just-about-the-brand-plan","html_content":"

Biopharma launches are being pressure-tested by access uncertainty, evidence scrutiny, pricing pressure, and tighter operating expectations. A strong brand plan still matters. But it is no longer enough.

","url":"https://routeconsultingllc.com/resources/f/launch-readiness-is-no-longer-just-about-the-brand-plan","title":"Launch Readiness Is No Longer Just About the Brand Plan","summary":"Biopharma launches are being pressure-tested by access uncertainty, evidence scrutiny, pricing pressure, and tighter operating expectations. A strong brand plan still matters. But it is no longer enough.","date_modified":"2026-05-06T18:55:31Z"},{"id":"https://routeconsultingllc.com/resources/f/commercializing-under-scrutiny","html_content":"

As digital channels scale, commercial leaders need to manage fair balance, context, and reputational risk as part of the growth agenda.

","url":"https://routeconsultingllc.com/resources/f/commercializing-under-scrutiny","title":"Commercializing Under Scrutiny","summary":"As digital channels scale, commercial leaders need to manage fair balance, context, and reputational risk as part of the growth agenda.","date_modified":"2026-04-22T14:15:45Z"},{"id":"https://routeconsultingllc.com/resources/f/from-promotion-to-proof","html_content":"

As access tightens and scrutiny grows, commercial success depends less on message volume and more on evidence credibility.

","url":"https://routeconsultingllc.com/resources/f/from-promotion-to-proof","title":"From Promotion to Proof","summary":"As access tightens and scrutiny grows, commercial success depends less on message volume and more on evidence credibility.","date_modified":"2026-04-14T14:02:24Z"},{"id":"https://routeconsultingllc.com/resources/f/evidence-is-the-new-commercial-advantage","html_content":"

As access tightens and scrutiny increases, brands will win less by amplifying messages and more by proving value in the settings where real decisions are made.

","url":"https://routeconsultingllc.com/resources/f/evidence-is-the-new-commercial-advantage","title":"Evidence Is the New Commercial Advantage","summary":"As access tightens and scrutiny increases, brands will win less by amplifying messages and more by proving value in the settings where real decisions are made.","date_modified":"2026-03-31T13:54:57Z"},{"id":"https://routeconsultingllc.com/resources/f/medicare-part-d-redesign-and-the-new-commercial-math","html_content":"

Why affordability, access, and plan economics now need to be managed as one system

","url":"https://routeconsultingllc.com/resources/f/medicare-part-d-redesign-and-the-new-commercial-math","title":"Medicare Part D Redesign and the New Commercial Math","summary":"Why affordability, access, and plan economics now need to be managed as one system","date_modified":"2026-03-25T21:10:25Z"},{"id":"https://routeconsultingllc.com/resources/f/your-bla-isn%E2%80%99t-the-finish-line%E2%80%A6%E2%80%A6it%E2%80%99s-the-audit","html_content":"

De-risking launch timelines by using FDA “Type” meetings as control points

","url":"https://routeconsultingllc.com/resources/f/your-bla-isn%E2%80%99t-the-finish-line%E2%80%A6%E2%80%A6it%E2%80%99s-the-audit","title":"Your BLA isn’t the finish line……it’s the audit","summary":"De-risking launch timelines by using FDA “Type” meetings as control points","date_modified":"2026-03-12T14:04:51Z"},{"id":"https://routeconsultingllc.com/resources/f/ai-hype-feels-%E2%80%9Cinevitable%E2%80%9D-until-you-ask-one-question","html_content":"

Generative vs Agentic AI in biopharma - what’s real today, and where it’s headed next

","url":"https://routeconsultingllc.com/resources/f/ai-hype-feels-%E2%80%9Cinevitable%E2%80%9D-until-you-ask-one-question","title":"AI hype feels “inevitable” until you ask one question","summary":"Generative vs Agentic AI in biopharma - what’s real today, and where it’s headed next","date_modified":"2026-03-03T17:49:23Z"},{"id":"https://routeconsultingllc.com/resources/f/fixed-costs-feel-%E2%80%9Csafe%E2%80%9D-until-they-don%E2%80%99t","html_content":"

Rethinking SG&A flexibility in biotech commercialization

","url":"https://routeconsultingllc.com/resources/f/fixed-costs-feel-%E2%80%9Csafe%E2%80%9D-until-they-don%E2%80%99t","title":"Reality of SG&A Management","summary":"Rethinking SG&A flexibility in biotech commercialization","date_modified":"2026-02-24T14:17:17Z"},{"id":"https://routeconsultingllc.com/resources/f/the-ultimate-guide-to-healthcare-marketing-strategies","html_content":"

Kickstarting Your Journey in Healthcare Marketing

","url":"https://routeconsultingllc.com/resources/f/the-ultimate-guide-to-healthcare-marketing-strategies","title":"The Ultimate Guide to Healthcare Marketing Strategies","summary":"Kickstarting Your Journey in Healthcare Marketing","date_modified":"2026-02-06T15:50:52Z"}]}